Enviar búsqueda
Cargar
I phar presentation-skolkovo_15.04.2013
•
Descargar como PPTX, PDF
•
0 recomendaciones
•
298 vistas
S
s_stankevich
Seguir
Empresariales
Salud y medicina
Denunciar
Compartir
Denunciar
Compartir
1 de 13
Descargar ahora
Recomendados
Making PrescriptionsPpersonal - Pharmacogenomics reports - Software in Medicine
Making PrescriptionsPpersonal - Pharmacogenomics reports - Software in Medicine
GDG Budapest
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
EPVC newsletter sixty three-April 2015
EPVC newsletter sixty three-April 2015
amin mohamed
Ziopharm oncology, inc. – product pipeline review – 2012
Ziopharm oncology, inc. – product pipeline review – 2012
Rose088
Inpharma startup village 30.04.13
Inpharma startup village 30.04.13
s_stankevich
City University business leader forum presentation
City University business leader forum presentation
Samuel Pun
ифар 15.04.13 сколково
ифар 15.04.13 сколково
s_stankevich
The impact of innovation on travel and tourism industries (World Travel Marke...
The impact of innovation on travel and tourism industries (World Travel Marke...
Brian Solis
Recomendados
Making PrescriptionsPpersonal - Pharmacogenomics reports - Software in Medicine
Making PrescriptionsPpersonal - Pharmacogenomics reports - Software in Medicine
GDG Budapest
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
Timo Minssen, "Regulatory exclusivities for pharmaceutical innovation in Europe"
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
EPVC newsletter sixty three-April 2015
EPVC newsletter sixty three-April 2015
amin mohamed
Ziopharm oncology, inc. – product pipeline review – 2012
Ziopharm oncology, inc. – product pipeline review – 2012
Rose088
Inpharma startup village 30.04.13
Inpharma startup village 30.04.13
s_stankevich
City University business leader forum presentation
City University business leader forum presentation
Samuel Pun
ифар 15.04.13 сколково
ифар 15.04.13 сколково
s_stankevich
The impact of innovation on travel and tourism industries (World Travel Marke...
The impact of innovation on travel and tourism industries (World Travel Marke...
Brian Solis
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Symposium
Basics of Pharmacology.pdf
Basics of Pharmacology.pdf
sktpharma
Regulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property Rights
santoshnarla
Nano far 2013_10_24_rogerio_gaspar
Nano far 2013_10_24_rogerio_gaspar
Rogério Gaspar
Ppt current projects rh 07 01
Ppt current projects rh 07 01
Healthy Ageing Campus Netherlands
Vladislav deigin peptide pharmaceuticals in russia and worlwide
Vladislav deigin peptide pharmaceuticals in russia and worlwide
igorod
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Danielle Labreche
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Danielle Labreche
Pambio Brochure 20160526
Pambio Brochure 20160526
Amos Ofer
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
ReportsnReports
BPHARM_3Y_6S_601T_Med.Chem dcndjk xczn nzcx .pdf
BPHARM_3Y_6S_601T_Med.Chem dcndjk xczn nzcx .pdf
pharmchemistry2020
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
RushikeshPalkar1
The current regulatory framework
The current regulatory framework
EURORDIS Rare Diseases Europe
Introduction in Pharmacology
Introduction in Pharmacology
Eneutron
Access Pharmaceuticals, Inc. Investor Presentation
Access Pharmaceuticals, Inc. Investor Presentation
accesspharma
R&D and Clinical trials at Gedeon Richter PLC.
R&D and Clinical trials at Gedeon Richter PLC.
Tristan Azbej, PhD
Session 3- Jurg Oliver Straub
Session 3- Jurg Oliver Straub
OECD Environment
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ...
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ...
Jagdish Gohil
Drugs.pdf
Drugs.pdf
Prof. Dr Pharmacology
Access Pharmaceuticals (ACCP)
Access Pharmaceuticals (ACCP)
Brett_Johnson
How to Get Started in Social Media for Art League City
How to Get Started in Social Media for Art League City
Eric T. Tung
Call Girls From Raj Nagar Extension Ghaziabad❤️8448577510 ⊹Best Escorts Servi...
Call Girls From Raj Nagar Extension Ghaziabad❤️8448577510 ⊹Best Escorts Servi...
lizamodels9
Más contenido relacionado
Similar a I phar presentation-skolkovo_15.04.2013
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Symposium
Basics of Pharmacology.pdf
Basics of Pharmacology.pdf
sktpharma
Regulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property Rights
santoshnarla
Nano far 2013_10_24_rogerio_gaspar
Nano far 2013_10_24_rogerio_gaspar
Rogério Gaspar
Ppt current projects rh 07 01
Ppt current projects rh 07 01
Healthy Ageing Campus Netherlands
Vladislav deigin peptide pharmaceuticals in russia and worlwide
Vladislav deigin peptide pharmaceuticals in russia and worlwide
igorod
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Danielle Labreche
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Danielle Labreche
Pambio Brochure 20160526
Pambio Brochure 20160526
Amos Ofer
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
ReportsnReports
BPHARM_3Y_6S_601T_Med.Chem dcndjk xczn nzcx .pdf
BPHARM_3Y_6S_601T_Med.Chem dcndjk xczn nzcx .pdf
pharmchemistry2020
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
RushikeshPalkar1
The current regulatory framework
The current regulatory framework
EURORDIS Rare Diseases Europe
Introduction in Pharmacology
Introduction in Pharmacology
Eneutron
Access Pharmaceuticals, Inc. Investor Presentation
Access Pharmaceuticals, Inc. Investor Presentation
accesspharma
R&D and Clinical trials at Gedeon Richter PLC.
R&D and Clinical trials at Gedeon Richter PLC.
Tristan Azbej, PhD
Session 3- Jurg Oliver Straub
Session 3- Jurg Oliver Straub
OECD Environment
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ...
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ...
Jagdish Gohil
Drugs.pdf
Drugs.pdf
Prof. Dr Pharmacology
Access Pharmaceuticals (ACCP)
Access Pharmaceuticals (ACCP)
Brett_Johnson
Similar a I phar presentation-skolkovo_15.04.2013
(20)
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Antisense Therapeutics (ASX: ANP) Investor Roadshow Presentation Sept 2015
Basics of Pharmacology.pdf
Basics of Pharmacology.pdf
Regulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property Rights
Nano far 2013_10_24_rogerio_gaspar
Nano far 2013_10_24_rogerio_gaspar
Ppt current projects rh 07 01
Ppt current projects rh 07 01
Vladislav deigin peptide pharmaceuticals in russia and worlwide
Vladislav deigin peptide pharmaceuticals in russia and worlwide
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Pambio Brochure 20160526
Pambio Brochure 20160526
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
BPHARM_3Y_6S_601T_Med.Chem dcndjk xczn nzcx .pdf
BPHARM_3Y_6S_601T_Med.Chem dcndjk xczn nzcx .pdf
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
The current regulatory framework
The current regulatory framework
Introduction in Pharmacology
Introduction in Pharmacology
Access Pharmaceuticals, Inc. Investor Presentation
Access Pharmaceuticals, Inc. Investor Presentation
R&D and Clinical trials at Gedeon Richter PLC.
R&D and Clinical trials at Gedeon Richter PLC.
Session 3- Jurg Oliver Straub
Session 3- Jurg Oliver Straub
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ...
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ...
Drugs.pdf
Drugs.pdf
Access Pharmaceuticals (ACCP)
Access Pharmaceuticals (ACCP)
Último
How to Get Started in Social Media for Art League City
How to Get Started in Social Media for Art League City
Eric T. Tung
Call Girls From Raj Nagar Extension Ghaziabad❤️8448577510 ⊹Best Escorts Servi...
Call Girls From Raj Nagar Extension Ghaziabad❤️8448577510 ⊹Best Escorts Servi...
lizamodels9
BAGALUR CALL GIRL IN 98274*61493 ❤CALL GIRLS IN ESCORT SERVICE❤CALL GIRL
BAGALUR CALL GIRL IN 98274*61493 ❤CALL GIRLS IN ESCORT SERVICE❤CALL GIRL
kapoorjyoti4444
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel
Business Model Canvas (BMC)- A new venture concept
Business Model Canvas (BMC)- A new venture concept
P&CO
PHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation Final
PanhandleOilandGas
Organizational Transformation Lead with Culture
Organizational Transformation Lead with Culture
Seta Wicaksana
Phases of Negotiation .pptx
Phases of Negotiation .pptx
nandhinijagan9867
Call Girls In Nangloi Rly Metro ꧂…….95996 … 13876 Enjoy ꧂Escort
Call Girls In Nangloi Rly Metro ꧂…….95996 … 13876 Enjoy ꧂Escort
dlhescort
Value Proposition canvas- Customer needs and pains
Value Proposition canvas- Customer needs and pains
P&CO
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
lizamodels9
Call Girls in Delhi, Escort Service Available 24x7 in Delhi 959961-/-3876
Call Girls in Delhi, Escort Service Available 24x7 in Delhi 959961-/-3876
dlhescort
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
daisycvs
Call Girls Service In Old Town Dubai ((0551707352)) Old Town Dubai Call Girl ...
Call Girls Service In Old Town Dubai ((0551707352)) Old Town Dubai Call Girl ...
allensay1
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Anamikakaur10
Call Girls Kengeri Satellite Town Just Call 👗 7737669865 👗 Top Class Call Gir...
Call Girls Kengeri Satellite Town Just Call 👗 7737669865 👗 Top Class Call Gir...
amitlee9823
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60% in 6 Months
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60% in 6 Months
IndeedSEO
Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
Sheetaleventcompany
(Anamika) VIP Call Girls Napur Call Now 8617697112 Napur Escorts 24x7
(Anamika) VIP Call Girls Napur Call Now 8617697112 Napur Escorts 24x7
Call Girls in Nagpur High Profile Call Girls
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...
Falcon Invoice Discounting
Último
(20)
How to Get Started in Social Media for Art League City
How to Get Started in Social Media for Art League City
Call Girls From Raj Nagar Extension Ghaziabad❤️8448577510 ⊹Best Escorts Servi...
Call Girls From Raj Nagar Extension Ghaziabad❤️8448577510 ⊹Best Escorts Servi...
BAGALUR CALL GIRL IN 98274*61493 ❤CALL GIRLS IN ESCORT SERVICE❤CALL GIRL
BAGALUR CALL GIRL IN 98274*61493 ❤CALL GIRLS IN ESCORT SERVICE❤CALL GIRL
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024
Business Model Canvas (BMC)- A new venture concept
Business Model Canvas (BMC)- A new venture concept
PHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation Final
Organizational Transformation Lead with Culture
Organizational Transformation Lead with Culture
Phases of Negotiation .pptx
Phases of Negotiation .pptx
Call Girls In Nangloi Rly Metro ꧂…….95996 … 13876 Enjoy ꧂Escort
Call Girls In Nangloi Rly Metro ꧂…….95996 … 13876 Enjoy ꧂Escort
Value Proposition canvas- Customer needs and pains
Value Proposition canvas- Customer needs and pains
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
Call Girls From Pari Chowk Greater Noida ❤️8448577510 ⊹Best Escorts Service I...
Call Girls in Delhi, Escort Service Available 24x7 in Delhi 959961-/-3876
Call Girls in Delhi, Escort Service Available 24x7 in Delhi 959961-/-3876
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Call Girls Service In Old Town Dubai ((0551707352)) Old Town Dubai Call Girl ...
Call Girls Service In Old Town Dubai ((0551707352)) Old Town Dubai Call Girl ...
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Call Girls Kengeri Satellite Town Just Call 👗 7737669865 👗 Top Class Call Gir...
Call Girls Kengeri Satellite Town Just Call 👗 7737669865 👗 Top Class Call Gir...
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60% in 6 Months
SEO Case Study: How I Increased SEO Traffic & Ranking by 50-60% in 6 Months
Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
Chandigarh Escorts Service 📞8868886958📞 Just📲 Call Nihal Chandigarh Call Girl...
(Anamika) VIP Call Girls Napur Call Now 8617697112 Napur Escorts 24x7
(Anamika) VIP Call Girls Napur Call Now 8617697112 Napur Escorts 24x7
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...
I phar presentation-skolkovo_15.04.2013
1.
IPHAR DRUG DEVELOPMENT FOR FOREIGN AND
DOMESTIC MARKETS 2013 Copyright © iPhar President Veniamin Khazanov Professor, MD, Ph.D., D.Sc.
2.
IPHAR IS A
HOLDING COMPANY Main activities: Development of innovative drugs for Russian and Global market Contract services - preclinical and clinical studies of drugs (over 60 studies for Russian and foreign customers in the last 3 years) 2013 Copyright © iPhar
3.
APIs screening Project “packaging” Attraction
of investments IP protection Drug formulation Technology scaling Preclinical research Clinical trials Registration Pilot manufacturing Commercialization Manufacturing and Sales Customers Development and Commercialization 2013 Copyright © iPhar Russian and foreign drug manufacturers Startup companies IPHAR – DRUG DEVELOPMENT SERVICES
4.
Commercialization department (preparing projects, attraction of investments,
IP protection) Management (planning, managemen t and control of all activities – from idea to implementation) Clinical department (clinical trials of new drugs in Russian clinical centers) Technological department (development and scaling drug synthesis technology) R&D center specializing in preclinical trials of drug safety and efficacy Team (over 60 employees, 6 D.Sc., 12 PhD) STRUCTURE OF IPHAR 2013 Copyright © iPhar
5.
INTERACTION WITH OTHER
ORGANIZATIONS Substance synthesis: TSU, OOO “Novohim” (Tomsk), NIOC SB RAS (Novosibirsk), OAO “Organica” (Novokuznetsk), etc. Laboratory analysis: TSU, TPU (Tomsk), institutes of SB RAS (Novosibirsk), institutes of RAMS and RAS (Moscow) Clinical trials: clinical centers of Tomsk, Novosibirsk, Kemer ovo and other Russian cities Russian and foreign pharmaceutical companies IPHAR 2013 Copyright © iPhaR
6.
ADVISORY BOARD Professor Khazanov
V. (iPhar) – pharmacologist, biochemist. Developer of over 100 drugs. Creator of a group of companies specializing in drug development and manufacture. – a prominent Russian chemist, inventor of 8 original drugs, author of 10 monographs on drug synthesis and development. Prof. Salakhutdinov N. (Scientific Institute of Organic Chemistry, Novosibirsk) – major Russian specialist in medical chemistry and drug synthesis. Prof. Gogvadze V. (Karolinska University, Sweden), D. Sci. – a major scientist in the field of molecular biology and toxicology. Dr. Schwarz J. (Nano Essentials Inc., Canada) – formerly one of the heads of formulation department of TEVA (Israel). Dr. Cleverley S. (ISIS Innovation, UK) – expert of Oxford University technology transfer center. Prof. Granik V. 2013 Copyright © iPhar
7.
2013 2014 2015
2016 1. Antiulcer drug – peptic ulcer and GERD 2. Anti-inflammatory - rheumatism, arthritis 3. Anti-Parkinson drug - Parkinson's disease 4. Antiplatelet - cardiovascular disease DEVELOPMENT OF INNOVATIVE DRUGS FOR GLOBAL MARKETS 2013 - 2015 IPHAR plans to complete preclinical studies of 4 innovative drugs and start clinical trials: 2013 Copyright © iPhar
8.
Product – new
molecule based on pyridopyrazindione with a new mechanism of action on H+/K+ ATPase: a reversible potassium- independent proton pump inhibitor. IP: Patent RU 2465274, priority date 05.03.2010; PCT/RU2011/000103; US application 13/602,239 dated 03.09.2012 (allowance for a patent dated 21.03.2013); EPO application 11750980.2 dated 04.10.2012; Ukraine and EAPO applications. Competitive advantages compared to the best drugs on the market (proton pump inhibitors ): • reversibly inhibits enzymes of gastric mucosa; • does not suppress normal gastric acid secretion level; • does not inhibit gastrointestinal peristalsis; • reduces the risk of night-time acid “breakthrough” and “rebound” – sudden increase in acidity after cancelling the drug. Consumer benefits – sustained normal digestion level in long-term treatment, reduction in adverse effects incidence and disease recurrence. ANTIULCER DRUG 2013 Copyright © iPhar
9.
The drug is
based on a new small molecule (terpenoid derivative), differing in its properties from the known antiparkinson compounds. IP rights - OOO«Rionis»: patent RU 2418577, priority date 24.12. 2009; PCT/RU2010/000778; US application No. 13/518,814 dated 22.06.2012; EPO application 10844832.5 dated 20.07.2012; EAPO application. Competitive advantages : •does not cause dyskynesia and other motor and non-motor adverse effects, present in levodopa; •effectiveness – as good as levodopa, unlike most competitors (dopamine agonists or MAO and COMT inhibitors); •can potentially have neuroprotective action and eliminate some non- motor disorders of Parkinson disease; •can be used to treat drug-induced parkinsonism. Consumer benefits : 1) Makes safe and long-term PD monotherapy possible; 2) Slows down the disease progression; 3) Eliminates non-motor disorders. ANTI-PARKINSON DRUG 2013 Copyright © iPhar
10.
Product - the
new patented compound - N-[3-(4-nitrophenylamino)-indole- 2-ilmethylene]aminoguanidine hydrochloride with a new mechanism of action - selective inhibition of inducible NO-synthase. IP: Patent RU 2478618, priority date 15.03.2010; PCT/RU 2011/000142; US application 13/634,840 dated 13.09.2012; EPO application 11756610.9 dated 12.10.2012; Ukraine and EAPO applications. The main advantage of the drug over the worldwide used analogs (NSAIDs) is the absence of dangerous ulcerogenic effects, because its pharmacological target is NO-synthase and not cyclooxygenase. Efficiency - the new compound exhibits anti-inflammatory action as potent as voltaren and indomethacin in peritonitis and arthritis models (ED50 – 50 mg/kg, mice, rats) Safety - the compound has low toxicity (LD50>5000 mg/kg, mice). Market. There are no direct market analogs of the new drug. World market of NSAIDs amounts to $10 billion. ANTI-INFLAMMATORY DRUG 2013 Copyright © iPhar
11.
Product – a
new molecule - indolinone-3 derivative with a new mechanism of action - a nitric oxide donor and a stimulator of soluble guanylate cyclase and cGMP synthesis. IP: Patent RU (application № 2011144895 dated 08.11.2011); PCT/RU2012/000884. Competitive advantages: Unlike aspirin, the new molecule does not have ulcerogenic side effect. Unlike the known antiplatelet drugs, it has anti- hypertensive and cardioprotective properties, reducing xenobiotic load, the incidence of adverse effects and costs of cardiovascular disease treatment. Efficacy is proven in in vitro (GC activity) and in vivo models (platelet aggregation, parenchymal hemorrhage, hypertension). Effective doses: 10 -7 mol in vitro, 4-12 mg/kg (per os), 0,01-1,0 mg/kg (intravenously). Low toxicity - LD50 = 8900 mg/kg in oral administration in mice. Market. The world antiplatelet drug market amounts to $15 billion. The novel drug aims to be a possible alternative to clopidogrel and new antiplatelet drugs (prasugrel, ticagrelor) used in CVD treatment. ANTIAGGREGANT (ANTIPLATELET DRUG) 2013 Copyright © iPhar
12.
Product – a
new molecule – glycyrrhetic acid derivative, a structural analogue of the known compound - Bardoxolone methyl (Reata Pharmaceuticals/ Abbott Laboratories), which underwent Phase III clinical trials as antioxidant inflammation modulator for the treatment of chronic kidney disease in type 2 diabetes. Mechanism of action – modulator of activity of transcription factors Nrf2k,NFkB and PPAR. Promising areas of application: 1) Oncology; 2) Neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, multiple sclerosis). IP: Patent RU 2401273 dated 30.03.2009; Russian patent application № 2012129738 dated 13.07.2012 Efficiency: proven anti-tumor activity in vitro at doses of 0,5 – 5x10-6 mol Low toxicity - LD50 > 5000 mg/kg in oral administration in mice. ANTICANCER DRUG 2013 Copyright © iPhar
13.
IPHAR President: Veniamin Khazanov, Professor,
MD, Ph.D., D.Sc. Address: Elizarovykh str. 79/4, Tomsk, Russia Tel./fax: +7(3822)248721 Mob.: +79138295599 e-mail: gen_dir@iphar.ru www.iphar.ru 2013 Copyright © iPhar
Descargar ahora